Archive for the ‘Allergy’ Category

Michigan patient safety study gets HHS approval to resume

Monday, March 3rd, 2008

A patient safety project that helped more than 100 Michigan hospital intensive care units cut their average catheter-related bloodstream infection rate by 66% can start collecting outcomes data again. That was the ruling last month from the Dept. of Health and Human Services’ Office for Human Research Protections.

The move was viewed widely as a reversal of OHRP’s controversial decision last fall to order the hospitals to suspend data collection. OHRP acted then because researchers had misclassified the project as being exempt from federal human research subject regulations and did not obtain informed consent from ICU patients.

(more…)

Finding one’s place (book excerpt: Intern: A Doctor’s Initiation)

Sunday, February 17th, 2008

In the fall I rotated through the geriatrics ward. One of the attending physicians was an irritating woman whose idea of the Socratic method was pimping you with really vague questions, then acting like she had already thought of whatever answers you gave and that you were only telling her what she already knew. The other attending was a throwback to “the days of the giants,” when pneumococcal pneumonia was diagnosed by injecting sputum into mice and antibiotics for urinary tract infections were tested on agar plates. One morning, one of my interns presented a case to him of an elderly man who had been hospitalized with fever and a cough producing green sputum. “He has pneumonia,” she proclaimed confidently. “Take a look at this chest X-ray.” She pulled up a digital image on a computer screen showing a distinct pneumonic streak. The senior physician waved it off. “First tell me about your lung exam,” he said.

(more…)

How to Reduce Puffy Eyes (Cure For Allergies)

Friday, February 15th, 2008

If you’re new here, you may want to subscribe to my RSS feed.Thanks for visiting!

Reduce puffy eyes and by allergies, sinus conditions, premenstral syndrome or even excess salt intake, as salt also causes water retention. Most people have puffy eyes when they

Do you have frequent or intense episodes of:
Do you have allergies? Take the Test! Give yourself one point for each “yes” answer and Puffy Eyes? Yes . No . Headaches? Yes . No . Facial Pain? Yes . No . Ear Popping? Yes . No

(more…)

Post Traumatic Stress Is a Risk Factor for Chronic Disease

Friday, February 15th, 2008

(Ivanhoe Newswire)  Veterans with Post Traumatic Stress Disorder (PTSD) are just as likely to have long term health problems as people with chronic disease risk factors like high white blood cell counts.  However, very few healthcare providers screen PTSD patients for these biological markers.

“Exposure to trauma has not only psychological effects, but it can take a serious toll on a person’s health status and biological function as well,” said Geisinger Health Systems Senior Investigator Joseph Boscarino, PhD, MPH.  “PTSD is a risk factor for disease that doctors should put on their radar screens.”

(more…)

President Signs Prescription Drug Safety Bill

Friday, December 21st, 2007

President Bush today signed a comprehensive Food and Drug Administration bill that focuses on prescription drug safety reforms. The bill holds the prescription drug industry more accountable for the safety of their products by requiring them to publicly disclose drug safety studies, even the ones that show their medicines in an unflattering light. It also increases the budget for drug safety reviews at the Food and Drug Administration.

Statement by CALPIRG Advocate Emily Rusch:

(more…)

GlaxoSmithKline antibiotic goes to FDA review

Friday, December 21st, 2007


The US Food and Drug Administration (FDA) has begun its review of GlaxoSmithKline’s (GSK) investigational antibacterial retapamulin. GSK submitted a new drug application (NDA) for retapamulin in November last year and expects to receive approval later this year.

Retapamulin was developed as a treatment for skin and skin structure infections due to susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. A GSK spokesman explained the importance of the new antibiotic.
(more…)

Pliva Pharma buys Novartis subsidiary

Friday, December 21st, 2007


Pliva is to buy a Spanish subsidiary from Novartis’ generics division Sandoz. The Croatian firm will pay 21.5 million euros for Uso Racional (UR), a well known and established generic brand in Spain with expected sales of 12 million euros for 2006.

A Pliva spokesman said: “The acquisition of UR represents a strong strategic fit with Pliva’s current Spanish operations, which Pliva expects to help it significantly strengthen its position and performance on this market.” The move comes as Pliva leaves the proprietary focussing solely on the generics following GlaxoSmithKline’s purchase of its Croatian research and development institute for $50 million.
(more…)

Healthy Snack Alternative

Friday, December 21st, 2007

If you’re new here, you may want to subscribe to my RSS feed.Thanks for visiting!

In a University of California, Los Angeles study of 36 elderly men and women, … Naturally, a Web site service provider to natural health stores nationwide. …

Acupuncture Schools | acupuncturetoday.com
… information on the school’s degree programs in acupuncture and Oriental medicine. … Yo San University of Traditional Chinese Medicine (Los Angeles) …

(more…)

Boehringer Ingelheim and Eli Lilly change Yentreve AriClaim deal

Friday, December 21st, 2007


Eli Lilly is to buy back worldwide marketing rights for Yentreve/AriClaim (duloxetine hydrochloride) from Boehringer Ingelheim. As a stress urinary incontinence (SUI) treatment, along with future related urinary incontinence indications, the drug will continue to be marketed outside the US by Lilly but other treatments using duloxetine will remain under both firms.

Lilly president and chief operating officer John Lechleiter said: “Based on our collective experiences to date in the marketplace, both companies believe that the Yentreve/AriClaim opportunity is best suited and can be best commercialised in markets outside the US with the support of one company. “This is about ‘right sizing’ our investments to address our greatest opportunities and the greatest patient needs.” Dr Alessandro Banchi, Boehringer Ingelheim chairman of the board of managing directors, added: “There has been an excellent spirit of collaboration in our alliance with Lilly.
(more…)

House Passes Prescription Drug Safety Reforms

Friday, December 21st, 2007

Senate to follow

The House today passed significant reforms to the Food and Drug Administration’s drug safety review system. Part of a comprehensive FDA bill, the bill was a compromise between Senate and House legislation that passed overwhelmingly earlier this year. The bill, which includes strong consumer protections, will be voted on in the Senate tomorrow.

Statement by CALPIRG’s Federal Health Care Advocate Paul Brown:

(more…)